Cmprehensive Insights about 8+ Companies and 8+ Pipeline Drugs in the Pipeline LandscapeDublin, May 23, 2023 (GLOBE NEWSWIRE) -- The "Primary Open Angle Glaucoma - Pipeline Insight, 2023" clinical ...

Slower visual field loss in patients with primary open-angle glaucoma was linked to greater physical activity, suggesting ...

Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Open-Angle Glaucoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A comprehensive analytical report has been ...

Disc hemorrhage location was associated with areas of clustered visual field progression in patients with primary open-angle ...

Diorasis Therapeutics has partnered with Northway Biotech to establish a scalable cGMP production process for DTx’s lead ...

Use of nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) is associated with an increased risk for primary open-angle glaucoma (POAG), according to a study published online June 20 ...

Filtration surgery effectively lowers IOP and slows central visual field deterioration in open-angle glaucoma and high myopia.

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma ...

Approximately half of all childhood glaucoma surgeries in the United States fail within the first year, according to AAO data.